Study guide

8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies

Key Takeaways Explain This Topic AI

Therapeutic acetaminophen is primarily eliminated via glucuronidation (40–67%) and sulfation (20–46%), with 5–10% oxidized by CYP2E1 to the cytotoxic electrophile N-acetyl-p-benzoquinone imine (NAPQI).

In overdose, sulfation and glucuronidation saturate; once glutathione stores are depleted by >70% (leaving <30% baseline), free NAPQI binds covalently to hepatic proteins, causing centrilobular (Zone 3) hepatic necrosis.

The Rumack-Matthew nomogram applies strictly to single acute ingestions presenting 4 to 24 hours post-ingestion, with a 4-hour treatment threshold of 150 mcg/mL; it cannot be applied to staggered, chronic, extended-release, or unknown-time ingestions.

Intravenous N-acetylcysteine (NAC) protocols include the standard 3-bag regimen (300 mg/kg over 21 hours) and the simplified 2-bag regimen (300 mg/kg over 20 hours); rate-dependent anaphylactoid reactions warrant temporarily pausing and slowing the rate rather than permanent discontinuation.

Massive ingestions (concentration above the 300 mcg/mL '2x' line at 4 hours) need an escalated third-bag NAC rate (commonly doubled); per the 2023 US/Canada consensus, NAC stops only when APAP is below 10 mcg/mL, INR is below 2.0, AST/ALT are normal or down 25–50% from peak, and the patient is well.

Last updated: October 2026

8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies

Note

Independent BCEMP study resource provided by ExamFinch. Content is organized around clinical toxicology and emergency medicine pharmacotherapy principles.

Pathophysiology & Hepatic Metabolism

Acetaminophen (N-acetyl-p-aminophenol, APAP) is the most widely utilized antipyretic and analgesic agent in North America and represents the leading cause of acute liver failure (ALF) in the United States. Understanding its dose-dependent metabolic fate is fundamental to emergency pharmacotherapy. ACETAMINOPHEN METABOLIC FATE

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Therapeutic Dosing: │
  • │ • Glucuronidation (UGT1A6, UGT1A9): 40%–67% ──> Nontoxic Glucuronide │
  • │ • Sulfation (SULT1A1): 20%–46% ───────────────> Nontoxic Sulfate │
  • │ • Renal Excretion (Unchanged): <5% │
  • │ • CYP2E1 Oxidation: 5%–10% ───────────────────> NAPQI (Electrophile) │
  • │ └─> Conjugated by Glutathione (GSH) ─────> Cysteine & Mercapturate │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ Toxic Overdose (>150 mg/kg or Massive Ingestion): │
  • │ 1. Glucuronidation and Sulfation pathways saturate │
  • │ 2. Shunting to CYP2E1 generates overwhelming quantities of NAPQI │
  • │ 3. Hepatic Glutathione stores depleted by >70% (<30% baseline reserves) │
  • │ 4. Free NAPQI binds covalently to cysteinyl sulfhydryls on hepatocyte │
  • │ macromolecules and mitochondrial membranes │
  • │ 5. Mitochondrial permeability transition pore opens ──> ATP depletion, │
  • │ ROS storm, and Centrilobular (Zone 3) Necrosis │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Cellular Mechanisms of Hepatotoxicity

Under therapeutic conditions, approximately 90% of acetaminophen undergoes Phase II hepatic conjugation via glucuronidation and sulfation into nontoxic, water-soluble metabolites excreted in the urine. Less than 5% is excreted unchanged. The remaining 5% to 10% is metabolized by cytochrome P450 isoenzymes—primarily CYP2E1 , with minor contributions from CYP1A2, CYP2D6, and CYP3A4—into the reactive, electrophilic intermediate N-acetyl-p-benzoquinone imine (NAPQI) .

In therapeutic dosing, NAPQI is rapidly neutralized by endogenous hepatic glutathione (L-gamma-glutamyl-L-cysteinylglycine, GSH) into nontoxic mercapturic acid and cysteine conjugates, which are eliminated renally. However, when an acute toxic ingestion occurs (>150 mg/kg or 7.5 to 10 g in adults):

Saturation of Phase II Conjugation : Hepatic sulfation saturates rapidly due to the depletion of inorganic sulfate cofactors, followed by saturation of glucuronidation.

Enhanced CYP2E1 Shunting : A substantially larger fraction of the APAP load is shunted through CYP2E1, accelerating the generation of NAPQI.

Critical Glutathione Depletion : Endogenous glutathione stores are consumed rapidly. When hepatic glutathione reserves fall below 30% of normal baseline (representing a >70% reduction), physiological detoxification fails.

Covalent Macromolecular Binding : Unbound, electrophilic NAPQI binds covalently to nucleophilic sulfhydryl groups on cysteinyl residues of cellular and mitochondrial proteins. This forms APAP-protein adducts, selectively damaging mitochondrial ATP synthase and respiratory complexes I and II.

Mitochondrial Permeability Transition : Mitochondrial membrane potential collapses, the mitochondrial permeability transition (MPT) pore opens, reactive oxygen species (ROS) and reactive nitrogen species (RNS) surge, ATP production ceases, and hepatocytes undergo oncotic necrosis.

Zonal Architecture & Centrilobular Necrosis

Hepatic injury manifests characteristically as centrilobular necrosis (Zone 3 necrosis) around the terminal hepatic venule. Zone 3 hepatocytes possess the liver's highest concentration of CYP2E1 enzymes and the lowest baseline reserves of glutathione and oxygen, making them exquisitely vulnerable to toxic oxidative injury compared to periportal (Zone 1) hepatocytes.

Clinical Stages of Acetaminophen Toxicity

Stage Time Post-Ingestion Clinical Manifestations Laboratory Findings

Stage I 0.5 to 24 hours Often completely asymptomatic, or mild anorexia, nausea, vomiting, diaphoresis, and general malaise. Serum transaminases (AST/ALT), bilirubin, and INR remain normal. Serum APAP concentration is detectable.

Stage II 24 to 72 hours 'Quiescent phase.' Nausea resolves, but right upper quadrant tenderness and hepatomegaly develop. Oliguria may occur. AST is the earliest and most sensitive marker of hepatotoxicity , beginning to rise by 24–36 hours (frequently > 1 , 000 IU/L >1,000\text{ IU/L} > 1 , 000 IU/L ). ALT, total bilirubin, and INR begin rising. BUN and serum creatinine may elevate.

Stage III 72 to 96 hours Peak hepatotoxicity. Severe jaundice, hepatic encephalopathy (asterixis, cerebral edema, coma), bleeding diathesis, profound hypoglycemia, and multiorgan failure. AST and ALT frequently peak > 10 , 000 – 20 , 000 IU/L >10,000–20,000\text{ IU/L} > 10 , 000–20 , 000 IU/L . Markedly elevated INR ( > 3.0 – 5.0 >3.0–5.0 > 3.0–5.0 ), severe hyperbilirubinemia, profound high anion gap lactic acidosis, and hyperammonemia.

Stage IV 4 days to 2 weeks Recovery or Death. In surviving patients, hepatic architecture regenerates completely without chronic cirrhosis due to hepatocyte replication. Transaminases, INR, and bilirubin gradually normalize over 1 to 3 weeks. Adducts clear. Sepsis, cerebral edema, or multiorgan failure are causes of death.

Important

Nephrotoxicity occurs in 10% to 25% of severe APAP ingestions, even in the absence of fulminant hepatic failure. Proximal tubular epithelial cells express CYP2E1 and prostaglandin H synthase, which locally generate NAPQI and cause acute tubular necrosis (ATN).

Rumack-Matthew Nomogram: Rules, Execution & Pitfalls

The Rumack-Matthew Nomogram is the definitive clinical tool for risk-stratifying acute acetaminophen overdose and guiding N-acetylcysteine (NAC) administration. Interpreting the nomogram requires strict adherence to its physiological boundaries.

The 150 Line (United States Treatment Line)

The standard nomogram plots serum acetaminophen concentration on a semi-logarithmic scale against time elapsed since ingestion:

Nomogram Bounds : Valid strictly between 4 hours and 24 hours post-ingestion.

Treatment Threshold (150-Line) : The United States treatment line starts at 150 mcg/mL (993 micromol/L) at exactly 4 hours post-ingestion and extends down to 37.5 mcg/mL at 12 hours , reflecting an assumed elimination half-life of 4 hours.

Safety Margin : The 150-line sits 25% below the original Rumack-Matthew line (which initiated at 200 mcg/mL at 4 hours). This 25% buffer was introduced to compensate for potential laboratory assay variance and errors in historical estimation of ingestion time.

Action Threshold : Any patient whose plotted APAP concentration falls on or above the 150-line must immediately receive N-acetylcysteine therapy.

The 4-Hour Rule

Serum APAP levels drawn prior to 4 hours post-ingestion cannot be interpreted on the nomogram . In the first 4 hours, oral absorption and tissue distribution are ongoing. A level drawn at 2 hours post-ingestion might reflect an ascending absorption curve, falsely reassuring clinicians while active absorption continues to climb toward toxic peaks. If an APAP level is drawn at 2 hours, a repeat level must be redrawn at or after the 4-hour mark to make treatment decisions.

Critical Nomogram Limitations

The Rumack-Matthew nomogram is invalid under any of the following circumstances:

Multiple / Staggered Ingestions : Ingestions of supratherapeutic doses spread over hours or days cannot establish a single 'time zero.'

Extended-Release Formulations : Acetaminophen ER products possess dual-layer matrix technology (immediate release combined with slow-release polymers), producing delayed or erratic secondary absorption peaks. Management requires drawing an initial level at 4 hours and a mandatory repeat level 4 to 6 hours later . If either level is above the line, or if the second level shows an upward trajectory, NAC is initiated.

Unknown Time of Ingestion : If ingestion timing is uncertain, the nomogram cannot be applied. Treat empirically with NAC if the APAP level is > 10 – 20 mcg/mL >10–20\text{ mcg/mL} > 10–20 mcg/mL or if AST/ALT are elevated.

Late Presentations (>24 Hours) : The nomogram terminates at 24 hours. Patients presenting > 24 >24 > 24 hours post-ingestion must be evaluated via transaminases, INR, and APAP concentration. If APAP is detectable or transaminases are elevated, initiate NAC immediately.

Co-Ingestants Altering Motility : Co-ingestion of antimuscarinics (diphenhydramine, tricyclic antidepressants) or opioids dramatically delays gastric emptying, potentially shifting peak concentrations beyond 4 hours.

N-Acetylcysteine (NAC) Pharmacology & Protocols

N-acetylcysteine is the specific antidote for acetaminophen toxicity. When administered within 8 hours of an acute ingestion, NAC provides near 100% hepatoprotection, virtually eliminating the risk of severe liver injury and death. However, NAC remains life-saving even when initiated > 8 – 24 >8–24 > 8–24 hours post-ingestion, as well as in patients with established fulminant hepatic failure.

Mechanisms of Action

Glutathione Precursor : Supplies exogenous L-cysteine, the essential rate-limiting substrate for intracellular synthesis of reduced glutathione (GSH).

Direct Glutathione Substitute : Directly binds and reduces free NAPQI via its own sulfhydryl group, converting it into harmless conjugates.

Sulfate Donor : Provides inorganic sulfate to facilitate non-toxic Phase II sulfation pathways.

Microcirculatory and Anti-inflammatory Resuscitation (Late Phase) : In established hepatotoxicity or fulminant hepatic failure, NAC serves as an antioxidant and free-radical scavenger, improves microvascular perfusion by increasing nitric oxide synthesis, optimizes cerebral and hepatic microcirculatory blood flow, improves oxygen extraction, and reduces cerebral edema and all-cause mortality.

Comparison of NAC Dosing Regimens

Regimen Induction / Loading Dose Intermediate Maintenance Terminal Maintenance Total Dose & Duration

Standard 3-Bag IV Regimen 150 mg/kg in 200 mL D5W over 1 hour 50 mg/kg in 500 mL D5W over 4 hours (12.5 mg/kg/h) 100 mg/kg in 1,000 mL D5W over 16 hours (6.25 mg/kg/h) 300 mg/kg over 21 hours

Simplified 2-Bag IV Regimen 200 mg/kg in 500 mL D5W over 4 hours (50 mg/kg/h) None (Eliminates intermediate bag) 100 mg/kg in 1,000 mL D5W over 16 hours (6.25 mg/kg/h) 300 mg/kg over 20 hours

Oral 72-Hour Regimen 140 mg/kg PO/NG loading dose 70 mg/kg PO/NG every 4 hours for 17 consecutive doses Continues every 4 hours through dose 17 1,330 mg/kg over 72 hours

Clinical Nuances of IV Regimens

Weight Capping : To prevent fluid overload, hyperosmolarity, and accidental overdosing, standard practice caps patient weight at 100 kg (or 110 kg per institutional policy). For example, a 140-kg patient receives doses calculated on 100 kg (max 15 g loading dose, 5 g second bag, 10 g third bag for the 3-bag protocol).

Advantages of the Simplified 2-Bag Regimen : Eliminating the rapid 1-hour loading bag dramatically reduces nurse programming errors, avoids delays between bags, and lowers peak plasma NAC concentrations, cutting the incidence of anaphylactoid reactions by approximately 50% without compromising hepatoprotection.

Oral Regimen Considerations : Oral NAC has an offensive sulfurous, rotten-egg odor. Solutions (10% or 20%) should be diluted to a 5% concentration with chilled soda, fruit juice, or chocolate milk and served cold in a covered cup with a straw. If a dose is vomited within 60 minutes of administration, redose immediately with an antiemetic (e.g., IV ondansetron 4–8 mg).

Non-IgE Anaphylactoid Reactions to IV NAC

Intravenous NAC frequently triggers anaphylactoid reactions in 10% to 20% of patients. These reactions occur predominantly during the initial rapid loading bag when serum NAC concentrations peak.

Pathophysiological Mechanism

This is a non-immunologic, rate-dependent, non-IgE-mediated reaction . NAC directly stimulates mast cells and basophils to release histamine without requiring prior sensitization or antibody formation. It is not an allergic reaction, and prior exposure is unnecessary.

Clinical Manifestations

Mild (Most Common) : Facial flushing, erythema, warmth, mild pruritus, and localized urticaria.

Moderate : Generalized urticaria, facial angioedema, nausea, tachycardia, and mild wheezing with normal oxygenation.

Severe (Rare, <1–2%) : Refractory bronchospasm, stridor, hypoxemia, or systemic hypotension.

  • Stepwise Management Algorithm ANAPHYLACTOID REACTION MANAGEMENT TO IV NAC
  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ 1. PAUSE THE INFUSION IMMEDIATELY │
  • │ • Stop the IV NAC infusion right away; do not disconnect the line. │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 2. SYMPTOM-DIRECTED PHARMACOTHERAPY │
  • │ • Mild / Flushing / Pruritus: IV Diphenhydramine 25–50 mg; famotidine 20mg│
  • │ • Bronchospasm: Inhaled Albuterol 2.5–5 mg nebulized │
  • │ • Severe Shock / Airway Edema: Intramuscular Epinephrine 0.3 mg (1:1,000)│
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 3. RESTART AT A REDUCED RATE │
  • │ • Once symptoms completely resolve (typically within 15–30 minutes): │
  • │ • Resume the remaining loading dose over a doubled time interval │
  • │ (e.g., infuse remaining load over 2 hours instead of 1 hour). │
  • │ • DO NOT PERMANENTLY DISCONTINUE NAC. │
  • └─────────────────────────────────────────────────────────────────────────────┘

Warning

Never permanently abandon N-acetylcysteine because of an anaphylactoid reaction. The mortality from untreated acetaminophen-induced acute liver failure is catastrophic, whereas non-IgE reactions are benign and easily controlled with antihistamines and infusion rate reduction.

Massive Acetaminophen Ingestions

A massive acetaminophen overdose is defined as an ingestion of > 30 – 40 g >30–40\text{ g} > 30–40 g or an APAP concentration falling substantially above the nomogram line (e.g., > 300 – 500 mcg/mL >300–500\text{ mcg/mL} > 300–500 mcg/mL at 4 hours, or > 2 × >2\times > 2 × the 150-treatment line).

Unique Clinical Presentation

Patients with massive APAP overdoses present with a distinct, early clinical syndrome that precedes the onset of transaminitis:

Direct Mitochondrial Inhibition : Circulating supratherapeutic concentrations of parent APAP and massive intracellular NAPQI inhibit mitochondrial electron transport complexes and cellular respiration.

Early Coma & Acidosis : Patients present within 6 to 12 hours post-ingestion with profound high anion gap metabolic lactic acidosis, early altered mental status or coma, and hypothermia— with completely normal AST/ALT .

Prolonged Half-Life : In massive ingestions, APAP metabolic pathways saturate completely, shifting elimination from first-order to zero-order kinetics. The elimination half-life can prolong from 2–4 hours to > 8 – 14 hours >8–14\text{ hours} > 8–14 hours .

Dose Escalation of NAC

Standard maintenance dosing (6.25 mg/kg/h in Bag 3) delivers approximately 38 mcmol/kg/h 38\text{ mcmol/kg/h} 38 mcmol/kg/h of cysteine, which is grossly inadequate to match the NAPQI production rate in massive ingestions, leading to breakthrough hepatotoxicity.

High-Risk Protocol : When the 4-hour level exceeds 300 mcg/mL 300\text{ mcg/mL} 300 mcg/mL , or exceeds 2 × 2\times 2 × the treatment line, the 2023 US/Canada consensus (Dart et al.) advises increasing the Bag 3 maintenance rate, typically to 1.5 to 2 times the standard rate (about 10 to 12.5 mg/kg/hour , for example doubling the third bag to 200 mg/kg over 16 hours). Fomepizole is sometimes added in very large ingestions to block CYP2E1, after toxicology consultation.

Extracorporeal Removal : Intermittent hemodialysis rapidly removes both parent APAP and toxic metabolites, while correcting profound lactic acidosis. When HD is initiated, the NAC infusion rate must be doubled to compensate for dialytic clearance of NAC.

Criteria for Discontinuing NAC Therapy

NAC therapy must never be discontinued solely because a patient has completed the standard 21-hour IV infusion or 72-hour oral protocol. Cessation must be strictly guided by objective clinical and laboratory criteria. CRITERIA FOR DISCONTINUING NAC

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Discontinuation is permitted ONLY when ALL four criteria are documented: │
  • │ │
  • │ 1. Serum APAP concentration is undetectable (<10 mcg/mL or below assay) │
  • │ 2. ALT/AST normal, or clearly declining (25% to 50% below peak) │
  • │ and are not actively rising │
  • │ 3. INR below 2.0 │
  • │ 4. Patient is clinically stable, awake, and asymptomatic │
  • └─────────────────────────────────────────────────────────────────────────────┘

These criteria follow the 2023 US/Canada consensus statement and the 2026 American College of Medical Toxicology practice statement on NAC duration. Some institutions use stricter local thresholds.

Actions When Criteria Are Not Met

If at the conclusion of Bag 3 (hour 20 or 21) the APAP concentration remains detectable ( > 10 mcg/mL >10\text{ mcg/mL} > 10 mcg/mL ) or transaminases are actively rising:

Continue Maintenance Infusion : Continue IV NAC at the Bag 3 rate ( 6.25 to 10 mg/kg/h ).

Repeat Labs : Recheck APAP, AST, ALT, total bilirubin, and INR every 4 to 6 hours .

Continue uninterrupted until all four criteria are fulfilled.